文献速递淋巴瘤

慢性淋巴细胞白血病细胞外泌体中的S100-A9蛋白在疾病进展中促进NF-κB活性

S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression.
PubMed 文献 · Blood · 2017-06-08

研究比较了惰性与进展性慢性淋巴细胞白血病(CLL)患者血浆外泌体的蛋白质组谱,发现进展性CLL及同一患者疾病进展后外泌体货物蛋白发生改变,涉及炎症、氧化应激及NF-κB和磷脂酰肌醇3-激酶/AKT通路激活;结果提示S100-A9蛋白在CLL进展中作为NF-κB通路激活因子发挥主要作用,白血病克隆可通过S100-A9表达、NF-κB激活和外泌体分泌形成自激活环路。

要点

  • 惰性与进展性CLL患者血浆外泌体蛋白质组谱不同。
  • 同一患者疾病进展前后外泌体蛋白质组谱存在差异。
  • S100-A9可能作为CLL进展中NF-κB通路的激活因子。

核心结论

  • 数据提出CLL中NF-κB激活的新途径,并强调外泌体作为促进CLL肿瘤进展的细胞外介质的重要性。
  • 结果提示S100-A9蛋白在CLL进展中作为NF-κB通路激活因子发挥主要作用,且白血病克隆可通过S100-A9表达、NF-κB激活和外泌体分泌形成自激活环路。

研究设计与样本

  • 研究比较了惰性与进展性CLL患者血浆外泌体的蛋白质组谱,以及同一患者疾病初发时与疾病进展期间的外泌体蛋白质组谱。

主要发现

  • 首次报告惰性与进展性CLL之间以及同一患者疾病初发与进展期间血浆外泌体蛋白质组谱不同。
  • 外泌体货物蛋白的改变仅见于进展性CLL患者疾病进展后,且这些改变凸显了与白血病进展相关的炎症、氧化应激及NF-κB和磷脂酰肌醇3-激酶/AKT通路激活的不同网络。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is an incurable disease characterized by accumulation of clonal B lymphocytes, resulting from a complex balance between cell proliferation and apoptotic death. Continuous crosstalk between cancer cells and local/distant host environment is required for effective tumor growth. Among the main actors of this dynamic interplay between tumoral cells and their microenvironment are the nano-sized vesicles called exosomes. Emerging evidence indicates that secretion, composition, and functional capacity of exosomes are altered as tumors progress to an aggressive phenotype. In CLL, no data exist exploring the specific changes in the proteomic profile of plasma-derived exosomes from patients during disease evolution. We hereby report for the first time different proteomic profiles of plasma exosomes, both between indolent and progressive CLLs as well as within the individual patients at the onset of disease and during its progression. Next, we focus on the changes of the exosome protein cargoes, which are found exclusively in patients with progressive CLL after disease progression. The alterations in the proteomic cargoes underline different networks specific for leukemia progression related to inflammation, oxidative stress, and NF-κB and phosphatidylinositol 3-kinase/AKT pathway activation. Finally, our results suggest a preponderant role for the protein S100-A9 as an activator of the NFκB pathway during CLL progression and suggest that the leukemic clone can generate an autoactivation loop through S100-A9 expression, NF-κB activation, and exosome secretion. Collectively, our data propose a new pathway for NF-κB activation in CLL and highlight the importance of exosomes as extracellular mediators promoting tumor progression in CLL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Prieto D, Sotelo N, Seija N, et al. S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression. Blood. 2017. PMID: 28596424. doi:10.1182/blood-2017-02-769851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。